相关实验视频
Updated: May 26, 2025

Monitoring Stub1-Mediated Pexophagy
Published on: May 12, 2023
药物向氧酶增殖器激活受体的药物
Zhouling Xie1, Jiwei Xin1, Chuping Huang1
1Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei, China.
2024年,两种新的过酶增殖器激活受体 (PPAR) 激动剂被批准用于原发性胆道胆炎 (PBC). 本综述涵盖了全球PPAR激动剂,它们的好处,缺点以及自2010年以来的最新发展.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
背景情况:
- 过氧体增殖器激活受体 (PPAR) 是关键的治疗点,有三种异型:PPARα,PPARγ和PPARδ.
- PPAR激动剂用于管理高脂血症,2型糖尿病 (T2DM) 和初级胆道胆炎 (PBC).
- 最近的进展导致了选择性和双/泛PPAR激动剂的开发,用于各种治疗应用.
研究的目的:
- 审查全球批准的PPAR激动剂,重点关注自2010年以来在市场上销售的药物.
- 总结PPAR激动剂作为治疗剂的优缺点.
- 突出PPAR激动剂治疗的近期发展,特别是在原发性胆道胆道炎 (PBC) 中.
主要方法:
- 全球批准的PPAR激动剂的综合文献搜索.
- 自2010年以来对PPAR激动剂的临床数据和监管批准的分析.
- 对不同PPAR激动剂的疗效,安全性和治疗应用进行比较的综述.
主要成果:
- 在2024年加速批准两种PPAR对PBC的激动剂,这标志着显著的进展.
- 选择性PPAR激动剂是治疗高脂血症,T2DM和PBC的既定治疗方法.
- 双/泛PPAR激动剂在更广泛的治疗适用性方面表现有前途.
结论:
- PPAR激动剂代表了一个充满活力的治疗开发领域,应用范围不断扩大.
- 该综述提供了已批准的PPAR激动剂的全面概述,有助于临床决策.
- 对PPAR激动剂的持续研究对于解决代谢和肝脏疾病中未满足的医疗需求至关重要.
更多相关视频
10:51Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
Peroxisomes
Protein Import into the Peroxisomes
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Prodrugs
Prodrugs help overcome...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Metabolism: Phase I Reactions